Newswire (Published: Thursday, September 26, 2019, Received: Thursday, September 26, 2019, 6:01:24 PM CDT)
Word Count: 551
2019 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Madison, Wisconsin, by NewsRx correspondents, research stated, “Prostate cancer (PRCA) is an androgen-driven disease, where androgens act through the androgen receptor (AR) to induce proliferation and survival of tumor cells. Recently, AR splice variant 7 (ARv7) has been implicated in advanced stages of PRCA and clinical recurrence.”
Financial supporters for this research include National Cancer Institute, National Institutes of Health, National Research Service Award, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences.
Our news editors obtained a quote from the research from the University of Wisconsin, “With the widespread use of AR-targeted therapies, there has been a rising interest in the expression of full-length AR and ARv7 in PRCA progression and how these receptors, both independently and together, contribute to adverse clinicopathologic outcomes. Despite a multitude of studies measuring the expression levels of AR and ARv7 in PRCA progression, the results have been inconsistent and sometimes contradictory due to technical and analytical discrepancies. To circumvent these inconsistencies, we used an automated multiplexed immunostaining platform for full-length AR and ARv7 in human PRCA samples and objectively quantified expression changes with machine learning-based software. With this technology, we can assess receptor prevalence both independently, and coexpressed, within specific tissue and cellular compartments. Full-length AR and ARv7 expression increased in epithelial nuclei of metastatic samples compared to benign. Interestingly, a population of cells with undetectable AR persisted through all stages of PRCA progression. Coexpression analyses showed an increase of the double-positive (AR(+)/ARv7(+)) population in metastases compared to benign, and an increase of the double-negative population in PRCA samples compared to benign. Importantly, analysis of clinicopathologic outcomes associated with AR/ARv7 coexpression showed a significant decrease in the double-positive population with higher Gleason score (GS), as well as in samples with recurrence in under 5 years. Conversely, the double-negative population was significantly increased in samples with higher GS and in samples with recurrence in under 5 years. Changes in AR and ARv7 coexpression may have prognostic value in PRCA progression and recurrence.”
According to the news editors, the research concluded: “A better understanding of the prevalence and clinicopathologic outcomes associated with changes in these receptors’ coexpression may provide a foundation for improved diagnosis and therapy for men with PRCA.”
For more information on this research see: Incidence of Androgen Receptor and Androgen Receptor Variant 7 Coexpression In Prostate Cancer. The Prostate, 2019;():. The Prostate can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.
The news editors report that additional information may be obtained by contacting W.A. Ricke, University of Wisconsin, School of Medicine, Dept. of Urology, Madison, WI 53705, United States. Additional authors for this research include J.E. Vellky, T.M. Bauman, E.A. Ricke and W. Huang.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/pros.23906. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
National Cancer Institute
National Institutes of Health
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Politics and Government
Government Agencies (U.S.)
Department of Health and Human Services
National Institutes of Health